[Interleukin-15 in pathogenesis of rheumatoid arthritis].
Shimada
Kota
K
Department of Rheumatology, Sagamihara National Hospital, NHO.
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology*; D023201:CD40 Ligand; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000502:physiology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D018836:Inflammation Mediators; D007375:Interleukin-1; D019409:Interleukin-15 / Q000276:immunology / Q000502:physiology*; D019718:Receptors, CXCR4; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2 / Q000502:physiology / Q000627:therapeutic use; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha
D000906:Antibodies; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; C508024:IL15RA protein, human; D018836:Inflammation Mediators; D007375:Interleukin-1; D019409:Interleukin-15; D019718:Receptors, CXCR4; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D023201:CD40 Ligand